Tissue Regenix Group
plc
('Tissue Regenix', the 'Group', or the
'Company')
Exercise of Options, Director
Dealing and Total Voting Rights
Tissue Regenix Group plc (AIM: TRX), the
regenerative medical devices company, announces that the Company
has issued and allotted 821,167 new ordinary shares of 0.1 pence
each ("Ordinary Shares") following the exercise of an aggregate
number of 821,167 share options (the "Options") by Daniel Lee
(Chief Executive Officer), David Cocke (Chief Financial Officer),
Kirsten Lund (PDMR) and other employees, issued under the Company's
Long-Term Incentive Plan. Each employee disposed of such number of
Ordinary Shares required to cover the associated cost attached to
the exercise of Options.
|
Numer of Options exercised
|
Numbers of Ordinary Shares sold
|
Price of Ordinary Shares sold
|
Resultant beneficial holding
|
% of issued share capital
|
Daniel Lee
|
283,216
|
87,611
|
61 pence
|
282,512
|
0.4
|
David Cocke
|
146,491
|
63,207
|
61 pence
|
154,489
|
0.2
|
Kirsten Lund
|
109,091
|
60,751
|
61 pence
|
113,557
|
0.2
|
Application has been made for the 821,167 new
Ordinary Shares to be admitted to trading on AIM. It is expected
that dealings in these new Ordinary Shares will commence at 8.00
a.m. on 27 June 2024. The new Ordinary Shares will rank pari passu
with the existing Ordinary Shares.
Following Admission, the Company will have in
issue a total of 71,395,635 Ordinary Shares. The Company does not
hold any Ordinary Shares in treasury. Therefore, the number of
total voting rights for the Company will be 71,395,635.
For more
information:
Tissue Regenix
Group plc
|
www.tissueregenix.com
|
David Cocke, Chief Financial Officer
|
via Walbrook
PR
|
|
|
Cavendish
Capital Markets Limited (Nominated Adviser and
Broker)
|
|
Emily Watts/Geoff Nash/George Dollemore -
Corporate Finance
|
|
Nigel Birks/Harriet Ward - ECM
|
|
|
|
Walbrook PR (Financial PR and IR)
|
Tel: +44
(0)20 7933 8780
|
Alice Woodings/Charlotte Edgar
|
TissueRegenix@walbrookpr.com
|
|
| |
About Tissue Regenix
(www.tissueregenix.com)
Tissue Regenix is a leading medical device
company in regenerative medicine. The Company's patented
decellularisation technology (dCELL®) removes DNA and other
cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold not rejected by the patient's body that
can be used to repair diseased or damaged body structures. Current
applications address many crucial clinical needs in sports
medicine, foot and ankle injuries, and wound care.
In August 2017, Tissue
Regenix acquired CellRight Technologies®. This biotech company
specialises in regenerative medicine and is dedicated to developing
high-quality, innovative tissue scaffolds to enhance healing
opportunities in defects created by trauma and disease. CellRight's
human tissue products may be used in spine, trauma, general
orthopaedic, dental and ophthalmological surgical
procedures.
Further details of the PDMR dealing are included below. This
information has been provided in accordance with Article 5(1)(b) of
the Market Abuse Regulation (EU) No 596/2014 which is part of UK
law by virtue of the European Union (Withdrawal) Act
2018.
1.
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
a)
|
Name
|
Daniel Lee
|
2.
|
Reason for the Notification
|
a)
|
Position/status
|
Chief Executive Officer
|
b)
|
Initial
notification/Amendment
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
Tissue Regenix Group plc
|
b)
|
LEI
|
213800PNOD5UHQUFJI36
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
a)
|
Description of the Financial
instrument, type of instrument
|
Ordinary Shares of 0.1p
each
|
Identification code
|
GB00B5SGVL29
|
b)
|
Nature of the transaction
|
Exercise of options and sale of
Ordinary Shares
|
c)
|
Price(s) and volume(s)
|
Options exercised: 283,216 Ordinary
Shares at an exercise price of 10 pence each
Ordinary Shares sold: 87,611 shares
at 61 pence each
|
d)
|
Aggregated information:
· Aggregated
volume
· Price
|
N/A
|
e)
|
Date of the transaction
|
18 June 2024
|
f)
|
Place of the transaction
|
London Stock Exchange, AIM
Market
|
1.
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
a)
|
Name
|
David Cocke
|
2.
|
Reason for the Notification
|
a)
|
Position/status
|
Chief Financial Officer
|
b)
|
Initial
notification/Amendment
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
Tissue Regenix Group plc
|
b)
|
LEI
|
213800PNOD5UHQUFJI36
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
a)
|
Description of the Financial
instrument, type of instrument
|
Ordinary Shares of 0.1p
each
|
Identification code
|
GB00B5SGVL29
|
b)
|
Nature of the transaction
|
Exercise of options and sale of
Ordinary Shares
|
c)
|
Price(s) and volume(s)
|
Options exercised: 146,491 Ordinary
Shares at an exercise price of 10 pence each
Ordinary Shares sold: 63,207 shares
at 61 pence each
|
d)
|
Aggregated information:
· Aggregated
volume
· Price
|
N/A
|
e)
|
Date of the transaction
|
18 June 2024
|
f)
|
Place of the transaction
|
London Stock Exchange, AIM
Market
|
1.
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
a)
|
Name
|
Kirsten Lund
|
2.
|
Reason for the Notification
|
a)
|
Position/status
|
PDMR
|
b)
|
Initial
notification/Amendment
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
Tissue Regenix Group plc
|
b)
|
LEI
|
213800PNOD5UHQUFJI36
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
a)
|
Description of the Financial
instrument, type of instrument
|
Ordinary Shares of 0.1p
each
|
Identification code
|
GB00B5SGVL29
|
b)
|
Nature of the transaction
|
Exercise of options and sale of
Ordinary Shares
|
c)
|
Price(s) and volume(s)
|
Options exercised: 109,091 Ordinary
Shares at an exercise price of 10 pence each
Ordinary Shares sold: 60,751 shares
at 61 pence each
|
d)
|
Aggregated information:
· Aggregated
volume
· Price
|
N/A
|
e)
|
Date of the transaction
|
18 June 2024
|
f)
|
Place of the transaction
|
London Stock Exchange, AIM
Market
|